Christian Itin: Okay, so thanks for joining, Kelly. Nice to have you on the call. First of all, in terms of the patient population, overall obviously the patient population is close, very close to what we’ve been seeing in the Phase I portion of the study. What we also expect to see is obviously some variability as we started going through the peak pandemic in the study as well, so we’re close. We may actually have seen even a bit of a worsening after that, and if we look at the ORR, obviously small numbers, but it went from 75% to 70%, which could be indicative of a slightly worse population, so that is, I think, where we are. We’re obviously going to present that in detail, the underlying patient characteristics, etc., at the full data presentation.
It’s going to be obviously an important piece of information that I think will help to put the data into the appropriate level of perspective as well, so that’s sort of the answer to the first question. What was the second question?
Kelly Shi: Thank you, super helpful. My second question is given the differentiated profile, especially on of AUTO1, would you consider exploring the opportunity in autoimmune indications such as lupus, given that some proof of concept data has been available? Thanks.
Christian Itin: Thanks for the question. Well, what you’re pointing to is a really remarkable data set that was developed by Andreas Mackensen and his team at the University of Erlangen, who have done a fantastic job evaluating the utility of a CD19 CAR T approach in patients with refractory systemic lupus. The outcome of the data was quite remarkable, there was a major medicine paper published at the end of last year. We know the team, actually had also worked with the team at the early stages of Blincyto development way back, almost 20 years back. Really good data set. We believe obviously that obe-cel has a remarkable profile, obviously now with a lot of data around the safety of the program, and clearly has an absolute outstanding safety profile which is important when you think about use in autoimmune disease.
The other aspect, of course, is that as we all learn in this space, the fundamental tricky part in this with autologous CAR T therapies is you actually have to have an ability to manufacture at scale and do that with quality and economically. Obviously that’s one of the key things we have been developing for obe-cel for its initial application in ALL. So absolutely, we’re following that field very closely. We think it is a very attractive potential future use of programs that are very safe and very active, and we believe obe-cel fits that very well.
Kelly Shi: Thank you.
Operator: Thank you. Our next question comes from the line of James Shin with Wells Fargo. Your line is open.
James Shin: Good morning and afternoon, guys. Just a couple from our end. I just want to dig a little deeper into the positioning of obe-cel. Do you envision obe-cel could be positioned ahead of Blincyto at some point, and is there a future study exploring this? Then on a related matter, cell therapy as a whole has started to make good headway with a couple oncologists. It seems there’s some regulatory hurdles, mainly the FACT immune effector cell accreditation, that makes cell therapy entering the community setting a little bit difficult or intensive. Any thoughts there? Really appreciate it.
